-
2
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
-
FLEX Study Team
-
Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31
-
(2009)
Lancet
, vol.373
, pp. 1525-31
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
3
-
-
77949886293
-
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
-
Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:918-27
-
(2010)
J Clin Oncol
, vol.28
, pp. 918-27
-
-
Khambata-Ford, S.1
Harbison, C.T.2
Hart, L.L.3
-
4
-
-
2342624080
-
EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
-
DOI 10.1126/science.1099314
-
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500 (Pubitemid 38720929)
-
(2004)
Science
, vol.304
, Issue.5676
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
5
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
DOI 10.1056/NEJMoa040938
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39 (Pubitemid 38637993)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.21
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
6
-
-
0036569870
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
-
DOI 10.1200/JCO.2002.10.112
-
Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J Clin Oncol 2002;20:2240-50 (Pubitemid 34441651)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.9
, pp. 2240-2250
-
-
Ranson, M.1
Hammond, L.A.2
Ferry, D.3
Kris, M.4
Tullo, A.5
Murray, P.I.6
Miller, V.7
Averbuch, S.8
Ochs, J.9
Morris, C.10
Feyereislova, A.11
Swaisland, H.12
Rowinsky, E.K.13
-
7
-
-
0034068319
-
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor- selective tyrosine kinase inhibitor
-
Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63 (Pubitemid 30305105)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.5
, pp. 2053-2063
-
-
Ciardiello, F.1
Caputo, R.2
Bianco, R.3
Damiano, V.4
Pomatico, G.5
De Placido, S.6
Bianco, A.R.7
Tortora, G.8
-
8
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:225-35
-
(2005)
PLoS Med
, vol.2
, pp. 225-35
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
9
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
DOI 10.1073/pnas.0709662105
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5 (Pubitemid 351439466)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.6
, pp. 2070-2075
-
-
Yun, C.-H.1
Mengwasser, K.E.2
Toms, A.V.3
Woo, M.S.4
Greulich, H.5
Wong, K.-K.6
Meyerson, M.7
Eck, M.J.8
-
10
-
-
0035023187
-
Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
-
Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001;40:297-306 (Pubitemid 32458155)
-
(2001)
Clinical Pharmacokinetics
, vol.40
, Issue.4
, pp. 297-306
-
-
Swaisland, H.1
Laight, A.2
Stafford, L.3
Jones, H.4
Morris, C.5
Dane, A.6
Yates, R.7
-
11
-
-
33745899929
-
Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics
-
DOI 10.2165/00003088-200645060-00006
-
Swaisland HC, Cantarini MV, Fuhr R, et al. Exploring the relationship between expression of cytocrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 2006;45:633-44 (Pubitemid 44046489)
-
(2006)
Clinical Pharmacokinetics
, vol.45
, Issue.6
, pp. 633-644
-
-
Swaisland, H.C.1
Cantarini, M.V.2
Fuhr, R.3
Holt, A.4
-
12
-
-
25144436285
-
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
-
Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1076-81
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 1076-81
-
-
Swaisland, H.C.1
Ranson, M.2
Smith, R.P.3
-
13
-
-
0036848833
-
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa)
-
Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of Epidermal Growth Factor Receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3496-502 (Pubitemid 35340727)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.11
, pp. 3496-3502
-
-
Heimberger, A.B.1
Learn, C.A.2
Archer, G.E.3
McLendon, R.E.4
Chewning, T.A.5
Tuck, F.L.6
Pracyk, J.B.7
Friedman, A.H.8
Friedman, H.S.9
Bigner, D.D.10
Sampson, J.H.11
-
14
-
-
0038166890
-
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
-
DOI 10.1016/S0169-5002(03)00189-2
-
Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:227-31 (Pubitemid 36842787)
-
(2003)
Lung Cancer
, vol.41
, Issue.2
, pp. 227-231
-
-
Cappuzzo, F.1
Ardizzoni, A.2
Soto-Parra, H.3
Gridelli, C.4
Maione, P.5
Tiseo, M.6
Calandri, C.7
Bartolini, S.8
Santoro, A.9
Crino, L.10
-
15
-
-
4143110253
-
Gefitinib in patients with brain metastasesfrom non-small-cell lung cancer: A prospective trial
-
DOI 10.1093/annonc/mdh276
-
Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004;15:1042-7 (Pubitemid 39089780)
-
(2004)
Annals of Oncology
, vol.15
, Issue.7
, pp. 1042-1047
-
-
Ceresoli, G.L.1
Cappuzzo, F.2
Gregorc, V.3
Bartolini, S.4
Crino, L.5
Villa, E.6
-
16
-
-
4944226682
-
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
-
DOI 10.1016/j.lungcan.2004.04.036, PII S0169500204002144
-
Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46:255-61 (Pubitemid 39330419)
-
(2004)
Lung Cancer
, vol.46
, Issue.2
, pp. 255-261
-
-
Hotta, K.1
Kiura, K.2
Ueoka, H.3
Tabata, M.4
Fujiwara, K.5
Kozuki, T.6
Okada, T.7
Hisamoto, A.8
Tanimoto, M.9
-
17
-
-
7444234824
-
Gefitinib in patients with brain metastases from non-small-cell lung cancer: Review of 15 clinical cases
-
Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004;6:123-8 (Pubitemid 39440210)
-
(2004)
Clinical Lung Cancer
, vol.6
, Issue.2
, pp. 123-128
-
-
Namba, Y.1
Kijima, T.2
Yokota, S.3
Niinaka, M.4
Kawamura, S.5
Iwasaki, T.6
Takeda, Y.7
Kimura, H.8
Okada, T.9
Yamaguchi, T.10
Nakagawa, M.11
Okumura, Y.12
Maeda, H.13
Ito, M.14
-
18
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
-
DOI 10.1200/JCO.2003.10.038
-
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46 (Pubitemid 46621858)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.12
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Tamura, T.4
Nakagawa, K.5
Douillard, J.-Y.6
Nishiwaki, Y.7
Vansteenkiste, J.8
Kudoh, S.9
Rischin, D.10
Eek, R.11
Horai, T.12
Noda, K.13
Takata, I.14
Smit, E.15
Averbuch, S.16
Macleod, A.17
Feyereislova, A.18
Dong, R.-P.19
Baselga, J.20
more..
-
19
-
-
0142055937
-
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
-
DOI 10.1001/jama.290.16.2149
-
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer. A randomized trial. JAMA 2003;290:2149-58 (Pubitemid 37432975)
-
(2003)
Journal of the American Medical Association
, vol.290
, Issue.16
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch Jr., T.J.4
Prager, D.5
Belani, C.P.6
Schiller, J.H.7
Kelly, K.8
Spiridonidis, H.9
Sandler, A.10
Albain, K.S.11
Cella, D.12
Wolf, M.K.13
Averbuch, S.D.14
Ochs, J.J.15
Kay, A.C.16
-
20
-
-
52049096854
-
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE) a randomized, phase II study
-
Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE) a randomized, phase II study. J Clin Oncol 2008;26:4253-60
-
(2008)
J Clin Oncol
, vol.26
, pp. 4253-60
-
-
Crino, L.1
Cappuzzo, F.2
Zatloukal, P.3
-
21
-
-
65549154268
-
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status
-
Goss G, Ferry D, Laurie S, et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60
-
(2009)
J Clin Oncol
, vol.27
, pp. 2253-60
-
-
Goss, G.1
Ferry, D.2
Laurie, S.3
-
22
-
-
33646867322
-
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
-
DOI 10.1097/01.cad.0000203381.99490.ab, PII 0000181320060400000005
-
Cufer T, Vrdoljak E, Gaafar R, et al. SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-9 (Pubitemid 44309982)
-
(2006)
Anti-Cancer Drugs
, vol.17
, Issue.4
, pp. 401-409
-
-
Cufer, T.1
Vrdoljak, E.2
Gaafar, R.3
Erensoy, I.4
Pemberton, K.5
-
23
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
-
DOI 10.1200/JCO.2004.08.001
-
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84 (Pubitemid 41103588)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
Scagliotti, G.4
Rosell, R.5
Miller, V.6
Natale, R.B.7
Schiller, J.H.8
Von Pawel, J.9
Pluzanska, A.10
Gatzemeier, U.11
Grous, J.12
Ochs, J.S.13
Averbuch, S.D.14
Wolf, M.K.15
Rennie, P.16
Fandi, A.17
Johnson, D.H.18
-
24
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
-
DOI 10.1200/JCO.2004.07.215
-
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94 (Pubitemid 41103589)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
Natale, R.B.4
Miller, V.5
Manegold, C.6
Scagliotti, G.7
Rosell, R.8
Oliff, I.9
Reeves, J.A.10
Wolf, M.K.11
Krebs, A.D.12
Averbuch, S.D.13
Ochs, J.S.14
Grous, J.15
Fandi, A.16
Johnson, D.H.17
-
25
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomized phase III trial
-
Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008;372:1809-18
-
(2008)
Lancet
, vol.372
, pp. 1809-18
-
-
Kim, E.S.1
Hirsch, V.2
Mok, T.3
-
26
-
-
52049125250
-
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
-
Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52
-
(2008)
J Clin Oncol
, vol.26
, pp. 4244-52
-
-
Maruyama, R.1
Nishiwaki, Y.2
Tamura, T.3
-
27
-
-
76749154617
-
Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
-
Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1307-14
-
-
Lee, D.H.1
Park, K.2
Kim, J.H.3
-
28
-
-
76649144669
-
Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials
-
Shepherd FA, Douillard J, Fukuoka M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. J Clin Oncol 2009;27(Suppl):S15
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Shepherd, F.A.1
Douillard, J.2
Fukuoka, M.3
-
29
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
DOI 10.1016/S0140-6736(05)67625-8, PII S0140673605676258
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37 (Pubitemid 41540110)
-
(2005)
Lancet
, vol.366
, Issue.9496
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Pereira, J.R.4
Ciuleanu, T.5
Von Pawel, J.6
Thongprasert, S.7
Tan, E.H.8
Pemberton, K.9
Archer, V.10
Carroll, K.11
-
30
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
DOI 10.1073/pnas.0405220101
-
Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11 (Pubitemid 39209661)
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.36
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
Doherty, J.4
Politi, K.5
Sarkaria, I.6
Singh, B.7
Heelan, R.8
Rusch, V.9
Fulton, L.10
Mardis, E.11
Kupfer, D.12
Wilson, R.13
Kris, M.14
Varmus, H.15
-
31
-
-
33750205340
-
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
-
DOI 10.1038/sj.bjc.6603393, PII 6603393
-
Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004 (Pubitemid 44606825)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.8
, pp. 998-1004
-
-
Asahina, H.1
Yamazaki, K.2
Kinoshita, I.3
Sukoh, N.4
Harada, M.5
Yokouchi, H.6
Ishida, T.7
Ogura, S.8
Kojima, T.9
Okamoto, Y.10
Fujita, Y.11
Dosaka-Akita, H.12
Isobe, H.13
Nishimura, M.14
-
32
-
-
33746789922
-
Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
-
DOI 10.1200/JCO.2005.05.4692
-
Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-6 (Pubitemid 46638887)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.21
, pp. 3340-3346
-
-
Inoue, A.1
Suzuki, T.2
Fukuhara, T.3
Maemondo, M.4
Kimura, Y.5
Morikawa, N.6
Watanabe, H.7
Saijo, Y.8
Nukiwa, T.9
-
33
-
-
33845262077
-
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
-
DOI 10.1038/sj.bjc.6603466, PII 6603466
-
Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006;95:1483-9 (Pubitemid 44863350)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.11
, pp. 1483-1489
-
-
Sutani, A.1
Nagai, Y.2
Udagawa, K.3
Uchida, Y.4
Koyama, N.5
Murayama, Y.6
Tanaka, T.7
Miyazawa, H.8
Nagata, M.9
Kanazawa, M.10
Hagiwara, K.11
Kobayashi, K.12
-
34
-
-
34247619676
-
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
-
DOI 10.1016/j.lungcan.2007.01.025, PII S0169500207000785
-
Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007;56:383-9 (Pubitemid 46679091)
-
(2007)
Lung Cancer
, vol.56
, Issue.3
, pp. 383-389
-
-
Sunaga, N.1
Tomizawa, Y.2
Yanagitani, N.3
Iijima, H.4
Kaira, K.5
Shimizu, K.6
Tanaka, S.7
Suga, T.8
Hisada, T.9
Ishizuka, T.10
Saito, R.11
Dobashi, K.12
Mori, M.13
-
35
-
-
40349111048
-
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
-
DOI 10.1038/sj.bjc.6604249, PII 6604249
-
Tamura K, Okamoto I, Kashii T, et al. West Japan Thoracic Oncology Group. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-14 (Pubitemid 351341609)
-
(2008)
British Journal of Cancer
, vol.98
, Issue.5
, pp. 907-914
-
-
Tamura, K.1
Okamoto, I.2
Kashii, T.3
Negoro, S.4
Hirashima, T.5
Kudoh, S.6
Ichinose, Y.7
Ebi, N.8
Shibata, K.9
Nishimura, T.10
Katakami, N.11
Sawa, T.12
Shimizu, E.13
Fukuoka, J.14
Satoh, T.15
Fukuoka, M.16
-
36
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
-
(2009)
N Engl J Med
, vol.361
, pp. 947-57
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
37
-
-
72449160988
-
A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung
-
Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 2009;4(Suppl):PRS.4
-
(2009)
J Thorac Oncol
, vol.4
, Issue.SUPPL.
-
-
Lee, J.S.1
Park, K.2
Kim, S.W.3
-
38
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
-
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
-
(2010)
Lancet Oncol
, vol.11
, pp. 121-8
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
39
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
North-East Japan Study Group
-
Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-8
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
40
-
-
8344230861
-
Gefitinib: A review of its use in the management of advanced non-small-cell lung cancer
-
DOI 10.2165/00003495-200464210-00008
-
Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004;64:2475-92 (Pubitemid 39480702)
-
(2004)
Drugs
, vol.64
, Issue.21
, pp. 2475-2492
-
-
Frampton, J.E.1
Easthope, S.E.2
-
41
-
-
10644261471
-
Overview of the tolerability of gefitinib (IRESSA™) monotherapy: Clinical experience in non-small-cell lung cancer
-
DOI 10.2165/00002018-200427140-00002
-
Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-92 (Pubitemid 39647851)
-
(2004)
Drug Safety
, vol.27
, Issue.14
, pp. 1081-1092
-
-
Forsythe, B.1
Faulkner, K.2
-
42
-
-
2942550603
-
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
-
DOI 10.1016/j.lungcan.2004.01.010, PII S0169500204000406
-
Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104 (Pubitemid 38757837)
-
(2004)
Lung Cancer
, vol.45
, Issue.1
, pp. 93-104
-
-
Takano, T.1
Ohe, Y.2
Kusumoto, M.3
Tateishi, U.4
Yamamoto, S.5
Nokihara, H.6
Yamamoto, N.7
Sekine, I.8
Kunitoh, H.9
Tamura, T.10
Kodama, T.11
Saijo, N.12
-
43
-
-
33745006872
-
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
-
DOI 10.1200/JCO.2005.04.9866
-
Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung Disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56 (Pubitemid 46630633)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.16
, pp. 2549-2556
-
-
Ando, M.1
Okamoto, I.2
Yamamoto, N.3
Takeda, K.4
Tamura, K.5
Seto, T.6
Ariyoshi, Y.7
Fukuoka, M.8
-
44
-
-
28444432176
-
The results of gefitinib prospective investigation
-
Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005;41:772-89
-
(2005)
Med Drug J
, vol.41
, pp. 772-89
-
-
Yoshida, S.1
-
45
-
-
84857647336
-
Iressa: Summary of product characteristics
-
Avalaible from [Last accessed 7 August 2009]
-
Iressa: summary of product characteristics. European Medicines Agency. Avalaible from http://www.emea.europa.eu/humandocs/PDFs/EPAR/iressa/emea- combined-h-1016-en.pdf [Last accessed 7 August 2009]
-
European Medicines Agency
-
-
-
46
-
-
63049132774
-
North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
-
Inoue A, Kobayashi K, Usui K, et al. North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400
-
(2009)
J Clin Oncol
, vol.27
, pp. 1394-400
-
-
Inoue, A.1
Kobayashi, K.2
Usui, K.3
-
47
-
-
79954606282
-
Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations
-
Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 2010;21(Suppl):LBA13
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL.
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
-
48
-
-
80053561215
-
Spanish Lung Cancer Group; Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial
-
Rosell R, Gervais R, Vergnenegre A, et al. Spanish Lung Cancer Group; Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011;29(Suppl):7503
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
, pp. 7503
-
-
Rosell, R.1
Gervais, R.2
Vergnenegre, A.3
-
49
-
-
80054731248
-
Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804)
-
Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 2011;29(Suppl):LBA7511
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Zhang, L.1
Shenglin, M.2
Song, X.3
|